🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

30 recruiting trials

for CML, Chronic Phase

Blinatumomab, Methotrexate, Cytarabine, and Ponatinib in Treating Patients With Philadelphia Chromosome-Positive, or BCR-ABL Positive, or Relapsed/Refractory, Acute Lymphoblastic Leukemia NCT03263572Phase 21 site📍 Houston M.D. Anderson Cancer Center · Tests: Blinatumomab, Cytarabine, Methotrexate, Ponatinib Autologous T Cells Transduced With Retroviral Vectors Expressing TCRs for Participant-specific Neoantigens in Patients With Hematologic Malignancies NCT06904066Phase 11 site📍 Bethesda National Cancer Institute (NCI) · Tests: aldesleukin, cyclophosphamide, fludarabine phosphate, Individual Patient TCR-Transduced PBL, TruSight Oncology (TSO) 500 Olverembatinib Combined With Venetoclax and Azacitidine in Blast Phase Ph Chromosome-positive CML NCT06757855Phase 1, Phase 21 site📍 Tianjin Institute of Hematology & Blood Diseases Hospital, China · Tests: Olverembatinib, Venetoclax, Azacitidine A Study on the Tolerability, Safety and Effectiveness of Asciminib in Patients With Philadelphia Chromosome-positive Chronic Myeloid Leukemia in the Chronic Phase in Germany NCT07549516n/a69 sites📍 Baden-Baden📍 Heidenheim📍 Schwäbisch Hall Novartis Pharmaceuticals Safety and Efficacy of Ponatinib for Treatment of Pediatric Recurrent or Refractory Leukemias, Lymphomas or Solid Tumors NCT03934372Phase 1, Phase 223 sites📍 Ghent📍 Paris📍 Paris Incyte Biosciences International Sàrl · Tests: Ponatinib HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant NCT03326921Phase 11 site📍 Seattle Fred Hutchinson Cancer Center · Tests: CD8+ and CD4+ Donor Memory T-cells-expressing HA1-Specific TCR, Bone Marrow Aspiration, Biospecimen Collection Edetate Calcium Disodium or Succimer in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Undergoing Chemotherapy NCT03630991Phase 11 site📍 Houston M.D. Anderson Cancer Center · Tests: Edetate Calcium Disodium, Multivitamin, Succimer A Real-world Chronic Myelogenous Leukemia (CML) Patient Disease Registry to Describe Patient Experience and Clinical Outcomes Among Patients With CML Receiving Approved First or Second Line Tyrosine Kinase Inhibitor (TKI) Therapy NCT07091019n/a17 sites📍 Birmingham📍 Stockton📍 Torrance Novartis Pharmaceuticals · Tests: TKIs Evaluation of Advanced Practice Nurse's Management of Patients With Chronic Myeloid Leukemia NCT06082804NA1 site📍 Avignon Centre Hospitalier Henri Duffaut - Avignon · Tests: APN and medical management, Medical management, Quality of life assessment, Treatment compliance assessment Study of Olverembatinib (HQP1351) in Patients With CML-CP NCT06423911Phase 3163 sites📍 Birmingham📍 Anchorage📍 Goodyear Ascentage Pharma Group Inc. · Tests: olverembatinib, Bosutinib Cladribine, Idarubicin, Cytarabine, and Venetoclax in Treating Patients With Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndrome, or Blastic Phase Chronic Myeloid Leukemia NCT02115295Phase 21 site📍 Houston M.D. Anderson Cancer Center · Tests: Cladribine, Cytarabine, Gilteritinib, Idarubicin, Laboratory Biomarker Analysis TGRX-678 Chinese Phase II in Chronic Myelogenous Leukemia (CML) Patients NCT06453902Phase 21 site📍 Beijing Shenzhen TargetRx Co., Ltd. · Tests: TGRX-678 ABL001 + Dasatinib + Prednisone + Blinatumomab in BCR-ABL+ B-ALL or CML NCT03595917Phase 14 sites📍 Chicago📍 Boston📍 Boston Marlise Luskin, MD · Tests: ABL001, Dasatinib, Prednisone, Blinatumomab Personalized NK Cell Therapy in CBT NCT02727803Phase 21 site📍 Houston M.D. Anderson Cancer Center · Tests: Allogeneic Natural Killer Cell Line NK-92, Anti-Thymocyte Globulin, Busulfan, Clofarabine, Cyclophosphamide MCW Alpha/Beta T-Cell and B-Cell Depletion With Targeted ATG Dosing NCT05794880NA1 site📍 Milwaukee Medical College of Wisconsin · Tests: Magnetic-Activated Cell Sorter (CliniMACS, Miltenyi) Open-label Study of Asciminib for CML-CP or CML-AP Patients With T315I Mutation Who Are Resistant, Intolerant or Ineligible to Ponatinib. NCT06514534Phase 26 sites📍 Bordeaux📍 Lille📍 Lyon Novartis Pharmaceuticals · Tests: ABL001/Asciminib Allogeneic Hematopoietic Cell Transplantation From HLA-matched Donor After Flu-Mel-PTCy Versus Flu-Mel-ATG Reduced-intensity Conditioning NCT03852407Phase 210 sites📍 Antwerp📍 Bruges📍 Brussels University of Liege · Tests: Thymoglobulin, Melphalan, Fludarabine, Cyclophosphamid ELVN-001 for the Treatment of Chronic Myeloid Leukemia With and Without T315I Mutation in Japanese Participants NCT06787144Phase 14 sites📍 Akita📍 Sapporo📍 Suita-shi Enliven Therapeutics · Tests: ELVN-001 Phase I Trial of Vididencel in CML-CP Patients With MRD Under TKI Treatment NCT07651878Phase 11 site📍 Bergen Mendus · Tests: vididencel Intensity Modulated Total Marrow Irradiation in Fully Human Leukocyte Antigen (HLA)-Matched and Partially-HLA Mismatched Allogeneic Transplantation Patients With High-Risk Acute Myeloid Leukemia (AML), Chronic Myeloid Leukemia (CML), and Myelodysplastic Syndrome (MDS) NCT06802315Phase 21 site📍 Chicago University of Illinois at Chicago · Tests: Intensity modulated total marrow irradiation, Cyclophosphamide (CTX), Fludarabine (Fludara), Busulfan (conditioning for… TGRX-678 US Phase I for Chronic Myelogenous Leukemia Patients NCT06088888Phase 12 sites📍 Houston📍 Seattle Shenzhen TargetRx Co., Ltd. · Tests: TGRX-678 Dexrazoxane Hydrochloride in Preventing Heart-Related Side Effects of Chemotherapy in Participants With Blood Cancers NCT03589729Phase 21 site📍 Houston M.D. Anderson Cancer Center · Tests: Cladribine, Cytarabine, Dexrazoxane Hydrochloride, Gemtuzumab Ozogamicin, Idarubicin Study to Determine the Efficacy and Safety of Asciminib in Pediatric Patients With Ph+ CML-CP NCT07354074Phase 234 sites📍 New Brunswick📍 New York📍 Cincinnati Novartis Pharmaceuticals · Tests: Asciminib single agent Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological Malignances NCT05092451Phase 1, Phase 21 site📍 Houston M.D. Anderson Cancer Center · Tests: Cyclophosphamide, CAR.70/IL15-transduced CB-NK cells, Fludarabine phosphate Selumetinib and Azacitidine in High Risk Chronic Blood Cancers NCT03326310Phase 11 site📍 Chicago University of Chicago · Tests: Azacitidine, Selumetinib Ponatinib in Chronic Myeloid Leukemia Patients in Chronic Phase NCT06119269n/a5 sites📍 Cagliari📍 Milan📍 Naples University of Pisa · Tests: Therapeutic drug monitoring, Molecular Response A Phase 3 Study for the Efficacy and Safety of Radotinib in CP-CML Patients With Failure or Intolerance to Previous TKIs NCT03459534Phase 318 sites📍 Barnaul📍 Kirov📍 Moscow Il-Yang Pharm. Co., Ltd. · Tests: Radotinib HCl Expanded/Activated Gamma Delta T-cell Infusion Following Hematopoietic Stem Cell Transplantation and Post-transplant Cyclophosphamide NCT03533816Phase 12 sites📍 Westwood📍 Columbus University of Kansas Medical Center · Tests: EAGD T-cell infusion (Phase I), EAGD T-cell infusion (Expansion) Phase I/II Trial: Engineered Donor Graft (Orca Q) for Pediatric Hematopoietic Cell Transplant (HCT) NCT05322850Phase 1, Phase 24 sites📍 Gainesville📍 Miami📍 Miami University of Florida · Tests: Orca-Q A Vaccine (CMV-MVA Triplex Vaccine) for the Enhancement of CMV-Specific Immunity and the Prevention of CMV Viremia in Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplant NCT07020533Phase 13 sites📍 Duarte📍 Atlanta📍 Boston City of Hope Medical Center · Tests: Biospecimen Collection, Electronic Health Record Review, Haploidentical Hematopoietic Cell Transplantation, Letermovir,…
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy